Skip to main content
. 2004 Jan 20;90(2):436–442. doi: 10.1038/sj.bjc.6601531

Figure 4.

Figure 4

Disease-free survival curves of stage I lung adenocarcinoma patients with low GalNAc-T3 expression or high GalNAc-T3 expression (n=78). The disease-free 3-year survival rates in the patients with low GalNAc-T3 expression and high GalNAc-T3 expression were 59 and 87.9%, respectively (P<0.01).